Abbreviated New Drug Application (ANDA), 21, 118. See also generic drug application; Hatch-Waxman Act (U.S., 1984)

Abilify (antipsychotic, Otsuka), 110–12
acceleration clauses, 57–59
Accupril (hypertension drug), 53–56
Actavis (drug company)
  FTC v. Actavis and, 24, 43–45, 49–50, 65
  product hopping of Namenda to Namenda XR, 76–78
Actelion (drug company), 82–83
active ingredient
defined, 27
strength of, 27
Actos (antidiabetic drug, Takeda), 58–59
Aleve (naproxen), 4
Alix line of cases, 84
Alnylam, 6
antitrust cases, 24. See also FTC v. Actavis as curb of citizen petitions as delay tactic, 133–35
  In re Cipro (California Supreme Court), 46–47
  In re Loestrin, 61, 64
  Noerr-Pennington cases, 99–100, 134
  rule of reason test in, 45–46
  Teva over provigil (narcolepsy drug), 47–48
  Trinko opinion, 134
Approved Drug Products with Therapeutic Equivalence Evaluations. See Orange Book
Argatroban (drug to prevent blood clotting), 117
Asacol (chronic ulcerative colitis drug, Warner Chilcott), 74–76
AstraZeneca
  product hopping of Prilosec to Nexium by, 71–74
automated generics, 59–60
automatic substitution laws, 20
Bayer, 46
Best Pharmaceuticals for Children Act (2002), 110
bioequivalency of generics, 22
Biogen, 6
biotech stocks concern over drop in at J.P. Morgan Healthcare Conference (2016), 1–2
Bloomberg, 1, 16
boy scout contract clauses, 59–61, 137
defined, 24
Product hopping by Endo and, 78–79
brand-name drug companies
costs to society of unscrupulous monopoly extensions and patent abuse by, 23
efforts of to block generic competition, 9
loss of market share after generic drug entry, 7
use of clinical trial data of by generic competitors, 22
business method patents, 83
carve-out requests, 103–04
carve-outs defined, 103
for generic Abilify (antipsychotic, Otsuka), 110–12
for generic Crestor (AstraZeneca), 108–10, 111–12
for generic Skelaxin (King Pharmaceuticals), 105–08
Celgene (pharmaceutical company), 85–84
Cipro (antibiotic, Bayer)
  In re Cipro antitrust case, 46–47
Index

Delzicol (chronic ulcerative colitis drug, Warner Chilcott), 74–76
Doryx (antibiotic and antimalarial drug, Warner Chilcott), 100–02
dosage form
  defined, 27
Drug Price Competition and Patent Term Restoration Act, 21, 32. See also Hatch-Waxman Act (U.S., 1984)
drug pricing. See pharmaceutical pricing and costs
drug product selection (DPS) laws, 20
drug safety and efficacy, 22, 28, 83
carve-out requests and, 103
citizenship claims of concerns over for product hogs and citizen petitions, 95
labeling information and, 109
subversion of FDA guidelines and, 67

Egypt, deal with Gilead, 5–6
Elements to Assure Safe Use (ETASU), 81–82
defined, 81
Endo Pharmaceuticals, 94–95
product hopping via boy scout contract clause by, 78–79
esomeprazole (Nexium), 4
evergreening, 69
defined, 69
exclusivity period
  180 days of under Paragraph IV certification, 22
  parking of, 39
FDA drug approval
  before 1962, 25
  changes after thalidomide crisis (1961), 28
  citizen petitions and, 97–98
denial rates of generic-related petitions between 2001 and 2010, 94
Food and Drug Administration Safety and Innovation Act (FDASIA) and, 97
generic delay and, 26
Kefauver-Harris Amendments and, 28
need for transparency in, 135–36
summary denial provision for citizen petitions and, 134

Federal Trade Commission (FTC)
on authorized generics, 60
decline in pay-for-delay settlements post-FTC v. Actavis, 46
FTC v. Actavis, 43–45, 49–50, 65
FTC v. Actavis rule of reason test, 45–46

citizen petitions
  FDA attempts to curb abuse of, 97–98
  FDA denial rates of, 94
  In re Suboxone case and, 95–97
  Mutual Pharmaceuticals ‘orange juice’ petition, 92–94
  number of filed since 2007 amendments, 98–99
  original purpose of, 113
  pharmaceutical company use of for generic delay, 91, 92
  Section 505(q) amendments and, 97–98
  sham citizen petitions assertions, 99–100
  staggered petitions for Doryx by Warner Chilcott, 100–02
  summary denial provision via 505(q) amendment, 99, 134
  as delay tactic, 25, 91, 92, 131
  by AstraZeneca for Crestor, 108–10, 111–12
  compilation of documents related to empirical analysis, 116
effectiveness of 2007 FDA amendments and, 28–31
  empirical evidence of rise in petitions with potential to delay generic applications, 99, 122–23
  by Endo for Opana, 94–95
  filing dates for generic applications and, 119–20
  identifying petitions that delay entry, 117–18
  key findings from empirical analysis of, 113–15, 122
  key metrics in, 121–22
  by King Pharmaceuticals for Skelaxin, 105–08
  matching petitions to relevant generic applications, 120–21
  need for FDA transparency in, 135–36
  overview of methodology of empirical analysis of, 115–17
  procedural block to curb, 132–33
  punitive deterrents to curb, 113–35
  simple prohibition to curb, 131–32
  staggered petitions and, 100–02
  timing data with generic applications and, 119
  timing of filing in relation to final approval, 123–28
  Colombia, 6
  Crestor (statin, AstraZeneca), 108–10, 111–12
  CVS Health, 5

Daraprim (antimalarial and HIV infections drug, Turing Pharmaceuticals), 9–10, 84
price increase in, 3

© in this web service Cambridge University Press
Felodipine. See Plendil (high blood pressure drug, Mutual Pharmaceuticals)
Flonase (allergy drug, GlaxoSmithKline), 68
Food and Drug Administration Amendments Act (2007), 33
Food and Drug Administration Safety and Innovation Act (FDASIA), 97
FTC v. Actavis, 24, 43–45, 49–50, 65
rule of reason test in, 45–46
Generation 1.0 strategies, 23–24. See also
Generation 2.0; Generation 3.0; pay-for-delay; reverse payment schemes
Generation 2.0 strategies, 24, 65. See also
Generation 1.0 strategies; Generation 3.0 strategies; pay-for-delay acceleration contract clauses, 57–59
boy scout contract clauses, 24, 59–61, 137
diminishment of pay-for-delay deals and, 66
FTC v. Actavis and, 65
In re Lipitor case of Pfizer v. Ranbaxy, 53–56
K-Dur case, 50–51, 52
King Drug case of Glaxo v. Teva, 61–65
no-authorized-generic, non-cash agreements and, 60–64
non-cash provisions post-Actavis and, 49–50
side deals in, 24, 59–52, 57, 59, 62, 65, 137, 139
Generation 3.0 strategies, 24–25, 65, 137. See also
Generation 1.0 strategies; Generation 2.0 strategies; pay-for-delay; REMS (Risk Evaluation and Mitigation Strategies)
Actelion case and, 82–83
boy scout contract clauses, 137
cut-out request for generic Abilify (antipsychotic, Otsuka), 110–12
cut-out request for generic Crestor (AstraZeneca), 108–10, 111–12
cut-out request for generic Skelaxin (King Pharmaceuticals), 103–08
Endo’s boy scout clause, 78–79
evergreening as obstruction strategy, 69
FDA acceptance of obstructionist petitions filed by brands against generics, 69
generic substitution systems as obstruction mechanism, 66–67
product hopping by Actavis from Namenda to Namenda XR, 76–78
product hopping of AstraZeneca from Prilosec to Nexium, 71–74
product hopping of Warner Chilcott of Asacol to Delzicol, 74–76
product hopping steps, 69–71
profits from obstructionist strategies for delay, 67–69
skinny labels and cut-out requests and, 103–04
subversion of FDA safety guidelines as, 67
generic competition
Big Pharma’s efforts to extend monopoly profits by blocking entry of, 9
effect on pharmaceutical pricing and costs and, 20–21
Hatch-Waxman Act as new era for, 21, 33
loss of market share for brand name drug companies and, 7
as patent cliff, 8
restricted distribution system and pricing controversy over Darapim, 9–10
restricted distribution system and pricing increases for Thioli (Retrophin), 10–11
threat of to pharma executives, 7
generic delay. See also
citizen petitions as delay tactic; Generation 2.0 strategies; Generation 3.0 strategies; pay-for-delay
costs to society of unscrupulous, 23
multiplicity tactics in, 25, 76, 137
generic drug application, 26–27. See also
Hatch-Waxman Act (U.S., 1984); Paragraph IV certification
requirements for an ANDA, 21–22
30 month stays on via patent infringement litigation, 31
generic drugs, 7
authorized generics, 59–60
Roche v. Bolar (U.S., 1984) and, 28
generic entry, 21–23. See also
Hatch-Waxman Act (U.S., 1984); Paragraph IV certification
citizens petitions and, 91
need of reform of, 25
rise in generic drugs and prescriptions, 22
slowness of before Hatch-Waxman Act, 21
generic substitution
automatic substitution laws, 20
automaticity of w/o patient intervention, 19, 20
Gilead
deal with Egypt on Sovaldi (hepatitis C drug), 5–6
monopoly profits from Sovaldi, 9
Sovaldi pricing (med for hepatitis C) and, 2
Gilenya (fringolimod, multiple sclerosis drug), 87
GlaxoSmithKline
generic delay of Flonase by, 68
King Drug case and, 61–65
Gleevec (leukemia treatment), 6
See also Paragraph IV certification
allowance of patent-protected brand-name
information for generic research, 26–27
amendments to, 33
complexity of as opportunity to hold off generic
competition, 25
expediting of generic applications before patent
expiration, 28
forfeiture provision for exclusivity period
adjustments, 39–40
forfeiture provision loopholes in 2003
amendment of, 40
generic drug applications and, 21–22, 26–27
new drugs non-patent exclusivities and, 32–33
as new era for generic competition, 21, 33
Orange book of brand name patents for generic
applications, 29–30, 55
purpose and complexity of, 26
restoration of time lost to approval processes for
pharmaceutical companies by, 32
skinny labels and carve-out requests and, 103–04
terms and acronyms defined, 26–27
HIV outbreak, 94
House Committee on Oversight and Government
Reform
Shkreli's questioning by in February 2016, 4

In re Cipro (antitrust case, California), 46–47
In re Flonase Antitrust Litigation, 68
In re K-Dur case, 52
In re Lipitor case, 53–56
In re Loestrin, 61, 64
In re Suboxone case, 87–90, 95–97
innovation, 12
intellectual property systems, 12

J.P. Morgan Healthcare Conference, 1, 12
concern and protests over rising pharmaceutical
prices at 2016 conference, 2, 4
concern over drop in stocks at 2016
conference, 1–2
defense of rising pharmaceutical prices at 2016
conference, 6–7
Martin Shkreli's lack of attendance at 2016
conference, 2
Journal of the American Medical Association, 5

Kaiser Family Foundation, 2
K-Dur (potassium deficiency drug, Schering-
Plough), 50–51, 52

Kefauver-Harris Amendments, 28
King Drug case, 61–65
King Pharmaceuticals, 105–08

labeling information
carve-outs and, 109
defined, 27
Lamictal (anticonvulsant drug, Glaxo), 61–65
launching at-risk, 55
Lipitor (statin drug, Pfizer), 53–56

MannKind, 3
MCMB Capital, 4
Medicare Modernization Act (2003), 33, 39
medication guides, 87
metaxalone. See Skelaxin
method-of-use patents, 103
monopoly profits, 9
Motrin, 4
MSMB Capital Management, 2
multiplicity tactics, in generic delay, 25, 76, 137

Mutual Pharmaceuticals
orange juice petition of, 92–94

Namenda and Namenda XR (Alzheimer’s drug, 
Actavis), 76–78
naproxen (Aleve), 4
NASDAQ’s Biotechnology Index, 1
new chemical entity (NCE) exclusivity, 32
New York Times, 4, 5
Nexium (esomeprazole), 4
monopoly profits from, 9
product hopping of from Prilosec, 71–74
Niacor-SR (cholesterol drug, Upsher-Smith), 50

no-authorized-generic agreements, 61–64
defined, 60

Noerr-Pennington cases, 99–100, 134
non-patent exclusivities, 32
Novartis, 6

NPR’s All Things Considered, 94

Obama, Barack
on rising costs of prescription medication, 5
off-label use of medication, 104
Opana (opioid painkiller, Endo), 94–95
Orange book, 29–30, 55
Orphan Drug Act, 33, 109
Orphan Drug Designation
for Abilify (antipsychotic, Otsuka), 110–12
for Crestor (statin, AstraZeneca), 108–10, 111–12
Paragraph IV certification, 22. See also Hatch-Waxman Act (U.S., 1984) defined, 29

duopoly and profits created by exclusivity period, 22, 30–31 exclusivity period elapsement for first generic filers and, 38

K-Dur case, 50–51, 52

patent infringement litigation and, 22 weak or misapplied patents for quick generic entry and, 29–30

patents, 7–9

allowance of patent-protected brand-name information for generic research via Hatch-Waxman Act, 26–27

business method patents, 84
costs to society of abuse of patent systems and, 23

defined, 8

method-of-use patents, 103

new drugs non-patent exclusivities in, 32–33

Orange book of Hatch-Waxman, 55

patent infringement litigation under Paragraph IV (Hatch-Waxman Act), 22

pharmaceutical explanation for strong patent rights, 8

weak drug patents, 20–30

pay-for-delay, 24, 34–35, 65, 137. See also Generation 2.0 strategies; Generation 3.0 strategies as anticompetitive, 41–43 as bottleneck to entry for generics, 38–39
cost to consumers in increased drug prices, 38 decrease in settlements post-FTC v. Actavis, 46, 66 diminishment of, 66

fines for UK pharma companies engaging in, 46

forfeiture provision for exclusivity period adjustments in Hatch-Waxman, 39–40

forfeiture provision loopholes and, 40

FTC v. Actavis, 42–45

FTC v. Actavis rule of reason test, 45–46

In re Cipro case (California Supreme Court) and, 46–47 increase in settlements since 2003 amendment, 40

non-cash provisions post-Actavis, 49–50 as procompetitive according to drug companies, 41 reverse payment schemes and, 35

settlement of Teva for provigil (narcolepsy drug), 47–48

side deals in, 24, 51–52, 57, 59, 62, 65, 157, 139

six-month duopoly period and, 36–37

pay-for-delay settlements is that the incentives of both the brand-name drug company and the generic company are aligned with each other – but not with society’s interests, 36

pediatric HoFN, 109, 112

pharmaceutical companies. See brand-name drug companies; by individual company

pharmaceutical economics, 13–19

pharmaceutical pricing and costs, 7 benefits of despite high prices and regulatory abuse, 12

cost of Big Pharma’s blocking of generic competition on, 9
generic competition effect on brand name drugs, 7
generics and, 20–21 increased drug prices via pay-for-delay, 38

Obama on rising costs of prescription medication, 5

overview of complexity of pharmaceutical economics, 13–19

pharma companies perspective on, 7

protests over Sovaldi pricing (hepatitis C drug, Gilead), 12

reports of global pricing scandals in media (2016), 4–6

restricted distribution system of Daraprim and, 9–10

restricted distribution system of Thiola (Retrophin) and, 10–11

schemes and tactics used by drug companies to keep prices high, 11, 12

sunshine laws and, 25

Valent Pharmaceuticals and, 3
Index

150 

pharmaceuticals  
benefits of despite high prices and regulatory 
abuse, 12  

Plendil (high blood pressure drug, Mutual  
Pharmaceuticals), 92–94  

Prilosec (AstraZeneca)  
product hopping of to Nexium, 71–74  
product hopping  
by Actavis from Namenda to Namenda  
XR, 76–78  
by AstraZeneca’s from Prilosec to  
Nexium, 71–74  
by Edon from Opana ER to Opana ER  
CRF, 94–95  

Endo’s boy scout clause and, 78–79  
evergreening and, 69  
steps in, 69–71  
by Warner Chilcott’s of Asacol to Delzicol, 
74–76  
defined, 61, 66  

Provigil (narcolepsy drug, Teva), 47–48, 51, 57–59  

Ranbaxy, 21  
In re Lipitor case of, 53–56  

Reckitt Benckiser (drug company)  
In re Suboxone case of, 87–90, 95–97  

reform of generic entry  
need for, 22  

REMS (Risk Evaluation and Mitigation  
Strategies)  
Actelion case and, 82–83  
bills against REMS abuse, 90–91  
Celgene REMS safety plan, 83–84  
defined, 80  

Elements to Assure Safe Use (ETASU) and, 81–82  
In re Suboxone case and, 87–90  
medication guide or communication plans  
and, 87  

Single Shared REMS program (SSRS), 87, 90  
specialty pharmacies and, 85–86  

Suboxone and, 81  

restricted distribution schemes  
Daraprim of Turing Pharmaceuticals, 9–10, 40  
as mandated by FDA safety protocols, 10  
specialty pharmacies and, 85–86  

Retrophin, 4  

restricted distribution system and pricing  
increases for Thiola, 10–11  

reverse payment schemes, 24, 35  
In re K-Dur case, 52  

In re Lipitor case, 53–56  

Revlimid (lenalidomide, Celgene), 83–84  

Roche v. Bolar (U.S., 1984), 28  

route of administration  
defined, 27  

rule of reason test, in antitrust cases, 45–46  

Sanofi, 6  

Schering-Plough  
K-Dur case, 50–51, 52  

Niacin-SR and, 50  

Section 305 amendments, 118  

Section 305(q) amendments, 97–98  
defined, 97, 99  

Shkreli, Martin, 84  
appearance at House Committee on Oversight  
and Government Reform (February 2016), 4  
arrest of, 4  

notoriety of in biotech, 2–3  
on patent cliff of generic drugs, 8  

price increase for Daraprim (antimalarial  
and HIV infections drug, Turing  
Pharmaceuticals), 3  

side deals, in pay-for-delay, 24, 51–52, 57, 59, 62, 
65, 137, 139  

Single Shared REMS program (SSRS), 87, 90  

Skelaxin (muscle relaxant, King), 105–08  
example of, 102  

Sovaldi (hepatitis C drug, Gilead), 12  
in Egypt, 5–6  

monopoly profits from, 9  

protests over pricing of, 2  
specialty pharmacies, 85–86  

strength of active ingredient  
defined, 27  

Suboxone (drug for opiate addiction, Reckitt  
Benckiser), 95–97  

In re Suboxone case and, 87–90  

REMS plan for, 51  
sunshine laws, 25  

Takeda (pharmaceutical company), 58–59  

Teva (pharmaceutical company), 47–48, 51  

acceleration clauses and, 58–59  

King Drug case and, 61–65  
thalidomide crisis, 28  

Thalomid (thalidomide, Celgene), 83–84  

Thiola (kidney drug, Retrophin), 10–11  

Tourette’s Syndrome, 110–12  

Trinko opinion, 134  

Turing Pharmaceuticals, 3. See also  
Shkreli, Martin
restricted distribution system and pricing controversy over Daraprim, 9–10

U.S. Supreme Court, 12
business method patents and, 84
decrease in pay-for-delay settlements
post-FTC v. Actavis, 46
FTC v. Actavis, 43–45, 49–50
FTC v. Actavis rule of reason test, 45–46
King Drug case and, 65
Noerr-Pennington cases, 99–100
Trinko opinion of, 134
UC Hastings Institute for Innovation Law, 11
United Kingdom
pay-for-delay fines for pharma companies in, 46
United Therapeutics, 7
Upsher-Smith
K-Dur case, 50–51, 52
Niacor-SR and, 50

use indications
defined, 27

Valent Pharmaceuticals
acquiring of Vimovo by, 4
exorbitant pricing by, 3
specialty pharmacies and, 85–86
Vimovo, 4
Vioxx (arthritis drug), 50

Wall Street Journal, 5

Warner Chilcott
denial of staggered petitions for Doryx, 100–02
product hopping of Asacol to Delzicol by, 74–76
weak drug patents, 29–30
generics companies success in challenging, 30
weak patent claims, 30, 33
Wu-Tang Clan, 3, 4